Isoginkgetin targets PLEKHA5 and suppresses PI3K/AKT/mTOR signaling in esophageal squamous cell carcinoma
Year: 2026
Type: article
Abstract: Aim of the study This study investigated the antitumor activity of isoginkgetin (IGK), a biflavonoid derived from Ginkgo biloba L., in esophageal squamous cell carcinoma (ESCC). Methods CCK-8, colony formation, EdU incorporation, wound-healing, Transwell, and flow-cytometric assays were used to characterize IGK-induced phenotypes. Integrated transcriptomic and data-independent acquisition proteomic analyses were used for abundance-based molecular profiling, while targeted antibody-based phosphorylation-array profiling was analyzed as a separate signaling-activity layer. Molecular docking and 100-ns molecular dynamics simulations assessed binding plausibility. SPR quantified direct IGK-PLEKHA5 binding, CETSA assessed IGK-dependent PLEKHA5 thermal stabilization, PLEKHA5 -overexpression experiments tested functional relevance, and a nude-mouse subcutaneous xenograft model assessed in vivo antitumor activity and tolerability within the measured endpoints. Results IGK inhibited ESCC cell proliferation, colony formation, migration, and invasion and induced G2/M arrest and apoptosis. Transcriptomic and proteomic profiles primarily reflected broad changes in cell-cycle, DNA-repair, p53-associated, and stress-response programs. Targeted phosphorylation-array analysis and immunoblotting showed reduced AKT and mTOR phosphorylation, together with changes in MAPK/ERK, GSK3α, and CREB-related signals. Cross-platform analysis showed significantly reduced PLEKHA5 protein abundance, accompanied by a downward trend in PLEKHA5 transcript expression. SPR showed concentration-dependent IGK-PLEKHA5 binding with an apparent equilibrium dissociation constant (K D ) of 9.266 μM, and CETSA showed IGK-dependent thermal stabilization of PLEKHA5. PLEKHA5 overexpression partially restored malignant phenotypes and AKT/mTOR phosphorylation. In vivo , IGK reduced xenograft growth and intratumoral PLEKHA5, p-AKT, p-mTOR, and Ki-67 signals without overt renal injury or increases in the measured inflammatory markers under the tested schedule. Conclusion These findings support PLEKHA5 as a direct binding target of IGK and indicate that PLEKHA5 contributes to the attenuation of AKT/mTOR signaling and the antitumor response in ESCC. The partial rescue following PLEKHA5 overexpression further suggests that additional IGK-responsive mechanisms are also involved.
Source: Frontiers in Pharmacology
Authors: Yanxin Dong(Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing), Xuben Niu(Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing), Wenting Song(Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing), Jiale Zhang(Investigation, Writing – original draft, Writing – review & editing), Shun Xie(Investigation, Writing – original draft, Writing – review & editing), Qiu Li(Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing), Shouyin Di(Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing), Taiqian Gong(Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing), Boshi Fan(Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing)
Language: English
Subfield: Organic Chemistry
Field: Chemistry
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $3,801
Award: G2601304044
OpenAlex ID: W7236038377
